The average one-year price target for Prelude Therapeutics (NasdaqGS:PRLD) has been revised to $4.42 / share. This is an increase of 23.81% from the prior estimate of $3.57 dated September 27, 2025.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $3.03 to a high of $5.25 / share. The average price target represents an increase of 187.01% from the latest reported closing price of $1.54 / share.
What is the Fund Sentiment?
There are 105 funds or institutions reporting positions in Prelude Therapeutics. This is an decrease of 29 owner(s) or 21.64% in the last quarter. Average portfolio weight of all funds dedicated to PRLD is 0.01%, an increase of 15.45%. Total shares owned by institutions decreased in the last three months by 12.29% to 27,562K shares. 
The put/call ratio of PRLD is 0.03, indicating a bullish outlook.
What are Other Shareholders Doing?
Orbimed Advisors holds 10,909K shares representing 24.94% ownership of the company. No change in the last quarter.
Baker Bros. Advisors holds 10,124K shares representing 23.14% ownership of the company. No change in the last quarter.
Price T Rowe Associates holds 928K shares representing 2.12% ownership of the company. In its prior filing, the firm reported owning 976K shares , representing a decrease of 5.23%. The firm decreased its portfolio allocation in PRLD by 8.92% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 720K shares representing 1.65% ownership of the company. No change in the last quarter.
PRHSX - T. Rowe Price Health Sciences Fund holds 661K shares representing 1.51% ownership of the company. In its prior filing, the firm reported owning 706K shares , representing a decrease of 6.71%. The firm increased its portfolio allocation in PRLD by 7.67% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
